Tagip 25mg Tablet contains Sitagliptin, an oral antidiabetic medicine used for the treatment of type 2 diabetes mellitus. It belongs to the DPP-4 inhibitor class, which works by increasing insulin release and decreasing glucose production in the body. It helps control blood sugar levels, especially after meals, and lowers the risk of diabetes-related complications when…
Tagipmet 50/500 mg Tablet combines Sitagliptin (50 mg) and Metformin (500 mg) to help manage blood glucose levels in type 2 diabetes, improving insulin response and lowering excess sugar production.
Select options
This product has multiple variants. The options may be chosen on the product page
100/1000 mg Tablet is an extended-release (XR) formulation containing Sitagliptin (100 mg) and Metformin (1000 mg), used for better long-term control of blood sugar in type 2 diabetes with once-daily dosing.
Select options
This product has multiple variants. The options may be chosen on the product page
TAGIPMET XR 100/500MG TAB is an extended-release, combination medication used to treat type 2 diabetes mellitus. It contains two active ingredients: sitagliptin (100mg) and metformin (500mg). Sitagliptin is a DPP-4 inhibitor that helps to increase insulin production and decrease glucose from the liver after meals. Metformin is a biguanide that reduces glucose production in the…
This pack of Tagipmet XR 50/1000 mg (20s) also contains Sitagliptin and Metformin (extended-release), used to manage type 2 diabetes by controlling blood glucose levels throughout the day.
Select options
This product has multiple variants. The options may be chosen on the product page
Tagipmet XR 50/500 mg Tablet contains Sitagliptin (50 mg) and Metformin (500 mg) in an extended-release form. It is used to manage type 2 diabetes by controlling blood sugar levels, improving insulin release, and reducing glucose production in the liver.
Select options
This product has multiple variants. The options may be chosen on the product page
Taivor 3 mg Tablet contains Tacrolimus, an immunosuppressant used to prevent organ transplant rejection and to treat certain autoimmune conditions by suppressing the immune system.
Select options
This product has multiple variants. The options may be chosen on the product page
Tamiso MR 0.4 mg Capsule contains Tamsulosin (modified release) which is used to relieve urinary symptoms caused by an enlarged prostate (benign prostatic hyperplasia), improving urine flow and reducing difficulty in urination.
Tamsol 0.4 mg Capsule contains Tamsulosin, used in the treatment of benign prostatic hyperplasia (BPH) to relax the prostate muscles and bladder neck, making it easier to urinate.
Select options
This product has multiple variants. The options may be chosen on the product page
Tamsol D Capsule contains Tamsulosin (0.4 mg) and Dutasteride (0.5 mg). It is used to treat enlarged prostate (BPH) by reducing the size of the prostate and relieving urinary symptoms.
Select options
This product has multiple variants. The options may be chosen on the product page
Tamsolin 0.4 mg Capsule contains Tamsulosin, used to treat urinary problems due to an enlarged prostate (benign prostatic hyperplasia). It helps relax prostate and bladder muscles, making urination easier.
Select options
This product has multiple variants. The options may be chosen on the product page
End of content
End of content
The Categories provide a framework to which existing art information systems can be mapped and upon which new systems can be developed. In addition, the discussions in the CDWA identify vocabulary resources and descriptive practices that will make information residing in diverse systems both more compatible and more accessible.The use of the CDWA framework will contribute to the integrity and longevity of data and will facilitate its inevitable migration to new systems as informational technology continues to evolve. Above all, it will help to give end-users consistent, reliable access to information, regardless of the system in which it resides.